(RTTNews) – IDEAYA Biosciences, Inc. (IDYA) reported further interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma patients. The trial confirmed overall response rate of 45%, disease control rate of 90% and